ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL

Bookmark and Share
Published: 15 Jun 2019
Views: 559
Rating:
Save
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

Prof Paolo Ghia speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about results from the ASCEND study testing acalabrutinib against rituximab with idelalisib or bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL) patients.

He reports that acalabrutinib was proven to be more effective than the other two drugs, with the progression-free survival (PFS) improved and the drug was also seen to be better tolerated.

Prof Ghia explains that this shows for the first time, in a randomised study, that monotherapy acalabrutinib can be an improvement on current treatment options.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.